First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
Status:
Completed
Trial end date:
2020-07-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended
Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a
kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation (Part 1: Dose
escalation) and to determine the safety and preliminary antitumor activity of JNJ-74699157 at
the RP2D regimen in participants with advanced solid tumors harboring a KRAS G12C mutation
(Part 2: Dose expansion).